https://orcid.org/0000-0001-8276-9320
References
- Alves VL, Gonçalves JL, Aguiar J, et al. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review. Crit Rev Toxicol. 2020;50(5):359–382.
- Hermanns-Clausen M, Müller D, Kithinji J, et al. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clin Toxicol (Phila)). 2018;56(6):404–411.
- Drenzek C, Geller RJ, Steck A, et al. Severe illness associated with synthetic cannabinoid Use-Brunswick, Georgia, 2013. MMWR Morbidity and Mortality Weekly Report. 2013;62(46):939.
- Jinwala FN, Gupta M. Synthetic cannabis and respiratory depression. J Child Adolesc Psychopharmacol. 2012;22(6):459–462.
- Richards JR, Schandera V, Elder JW. Treatment of acute cannabinoid overdose with naloxone infusion. Toxicology Communications. 2017;1(1):29–33.
- Jones JD, Nolan ML, Daver R, et al. Can naloxone be used to treat synthetic cannabinoid overdose? Biol Psychiatry. 2017;81(7):e51–e52.
- Alon MH, Saint-Fleur MO. Synthetic cannabinoid induced acute respiratory depression: Case series and literature review. Respir Med Case Rep. 2017;22:137–141.
- Schmid K, Niederhoffer N, Szabo B. Analysis of the respiratory effects of cannabinoids in rats. Naunyn Schmiedebergs Arch Pharmacol. 2003;368(4):301–308.
- Justinova Z, Tanda G, Munzar P, et al. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys . Psychopharmacology (Berl)). 2004;173(1-2):186–194.
- Haney M, Ramesh D, Glass A, et al. Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers. Neuropsychopharmacology. 2015;40(11):2489–2498.